13 March 2023

BIOPHARMA CREDIT PLC

(the "Company")

STATEMENT REGARDING SILICON VALLEY BANK

Pharmakon Advisors, LP, ("Pharmakon"), the investment adviser of the Company, notes the recent news reports regarding Silicon Valley Bank (together with its UK subsidiary, collectively, "SVB") being placed in receivership by US regulators. The Company does not hold deposits or other investments in SVB. In addition, Pharmakon has consulted with all of the Company's borrowers and is pleased to reiterate that they also have no significant exposure to SVB.

-Ends-

Enquiries

Buchanan

David Rydell / Mark Court / Jamie Hooper / Henry Wilson

+44 (0) 20 7466 5000

biopharmacredit@buchanan.uk.com

Notes to Editors

BioPharma Credit PLC is London's only specialist debt investor to the life sciences industry and joined the LSE in March 2017. The Company seeks to provide long-term shareholder returns, principally in the form of sustainable income distributions from exposure to the life sciences industry. The Company seeks to achieve this objective primarily through investments in debt assets secured by royalties or other cash flows derived from the sales of approved life sciences products.

LEI: 213800AV55PYXAS7SY24